Patents Assigned to MITOCHONDRIA EMOTION, INC.
-
Patent number: 11141390Abstract: Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.Type: GrantFiled: July 22, 2020Date of Patent: October 12, 2021Assignee: Mitochondria Emotion, Inc.Inventor: Gerald W. Dorn, II
-
Publication number: 20210251925Abstract: Compounds and compositions including stereoisomers of 6-phenylhexanamide derivative small molecule mitofusin activators are described. In particular, mitofusin activators comprising derivatives of (trans-4-hydroxycyclohexyl)-6-phenylhexanamide, which are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin-1 (MFN1) and/or mitofusin-2 (MFN2), or mitochondrial dysfunction, are described. Methods of treatment and pharmaceutical formulations are also described.Type: ApplicationFiled: April 30, 2021Publication date: August 19, 2021Applicant: MITOCHONDRIA EMOTION, INC.Inventor: Gerald W. DORN, II
-
Publication number: 20210251927Abstract: Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.Type: ApplicationFiled: April 30, 2021Publication date: August 19, 2021Applicant: MITOCHONDRIA EMOTION, INC.Inventor: Gerald W. DORN, II
-
Patent number: 11083699Abstract: Compounds and compositions including stereoisomers of 6-phenylhexanamide derivative small molecule mitofusin activators are described. In particular, mitofusin activators comprising derivatives of (trans-4-hydroxycyclohexyl)-6-phenylhexanamide, which are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin-1 (MFN1) and/or mitofusin-2 (MFN2), or mitochondrial dysfunction, are described. Methods of treatment and pharmaceutical formulations are also described.Type: GrantFiled: July 22, 2020Date of Patent: August 10, 2021Assignee: Mitochondria Emotion, Inc.Inventor: Gerald W. Dorn, II
-
Patent number: 11026904Abstract: Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.Type: GrantFiled: November 3, 2020Date of Patent: June 8, 2021Assignee: Mitochondria Emotion, Inc.Inventor: Gerald W. Dorn, II
-
Publication number: 20210046028Abstract: Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.Type: ApplicationFiled: November 3, 2020Publication date: February 18, 2021Applicant: MITOCHONDRIA EMOTION, INC.Inventor: Gerald W. DORN, II
-
Publication number: 20200345668Abstract: Compounds and compositions including stereoisomers of 6-phenylhexanamide derivative small molecule mitofusin activators are described. In particular, mitofusin activators comprising derivatives of (trans-4-hydroxycyclohexyl)-6-phenylhexanamide, which are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin-1 (MFN1) and/or mitofusin-2 (MFN2), or mitochondrial dysfunction, are described. Methods of treatment and pharmaceutical formulations are also described.Type: ApplicationFiled: July 22, 2020Publication date: November 5, 2020Applicant: MITOCHONDRIA EMOTION, INC.Inventor: Gerald W. DORN, II
-
Publication number: 20200345669Abstract: Compositions including small molecule mitofusin activators are described. The mitofusin activators are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (MFN1) and/or mitofusin 2 (MFN2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that activate mitochondrial fusion are also described.Type: ApplicationFiled: July 22, 2020Publication date: November 5, 2020Applicant: MITOCHONDRIA EMOTION, INC.Inventor: Gerald W. Dorn, II